Eye DiseasesIRISRegistryNCT02485847
IRIS Registry: Intelligent Research in Sight Registry
An observational study of Eye Diseases, run by American Academy of Ophthalmology at 1 site in United States.
Trial summary
The IRIS™ Registry (Intelligent Research in Sight) is the nation's first comprehensive eye disease clinical registry. The American Academy of Ophthalmology is developing it as part of the profession's shared goal of continual improvement in the delivery of eye care.The IRIS Registry will be a centralized system for… Read more about this study
- Who is it for?
- Ages 6 months and older
- Conditions the study is for
- Eye Diseases
- What is being tested?
- Ophthalmology
- Type of treatment
- Surgery or procedure
- How many people
- 20,000,000 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2014to Jan 2100
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: To ensure the IRIS Registry infrastructure is properly developed with features and functionalities that meets the needs of ophthalmologists, the IRIS Registry is currently only open to Academy members practicing in the United States and its territories.
Who may be able to join
- Patients who meet the denominator requirements for each measure.
Who cannot join
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
American Academy of Opthalmology
San Francisco, California, 94109
Andy Khuong, 415-561-8500, irisregistry@aao.org
About this study
The IRIS™ Registry (Intelligent Research in Sight) is the nation's first comprehensive eye disease clinical registry. The American Academy of Ophthalmology is developing it as part of the profession's shared goal of continual improvement in the delivery of eye care.The IRIS Registry will be a centralized system for ophthalmology practices to promote practice innovations and achieve clinical excellence.
Read the detailed description
The IRIS Registry is primarily a clinical self-improvement tool. It will allow ophthalmologists to compare their patient outcomes, professional performance and care processes against other ophthalmologists across the country. The IRIS Registry will be able to measure the continuum of care from initial patient contact, through intervention and follow up.
Improve Patient Care - Monitor patient interactions, track interventions, identify and address gaps in quality of care, and measure quality outcomes.
Manage Patient Populations - Proactively manage clinical conditions for entire patient populations by running reports on specific care criteria.
Benchmark Your Practice - Identify practice strengths and weaknesses using the IRIS Registry's ophthalmology-specific clinical data from other practices to compare to the performance and outcomes data of your practice.
Run quality reports on demand - Providing clinician- and practice-level results, plus national results and patient-level detail for all IRIS Registry measures.
Enhance Quality and Practice Efficiency - Use the IRIS Registry data to analyze practice processes and procedures and as a source for fact-based decision-making. Because the IRIS Registry will capture data over time at the individual and practice level, it will help practices efficiently manage patient care and optimize practice resources.
Join a Community of Quality - Become a member of a like-minded community of quality-driven professionals striving to continuously improve patient care. Interact with your peers to create opportunities for sharing quality improvement strategies and broaden your professional network.
- Conditions
- Eye Diseases
- Being tested
- Ophthalmology
- Keywords
- Eye Diseases
- Medical subject headings
- Eye Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OphthalmologyProcedure or surgery
A registry of ophthalmic ambulatory encounters which captures essential data elements for continuous quality improvement efforts, enhanced patient care outcomes, and pay for performance programs.
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
This measure is to be reported a minimum of once per reporting period for patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with primary open-angle glaucoma (in either one or both eyes) will submit this measure.
Measured: Up to 5 years
Age-Related Macular Degeneration (AMD): Dilated Macular Examination
This measure is to be reported a minimum of once per reporting period for patients, aged 50 years and older, seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with age-related macular degeneration (in either one or both eyes) will submit this measure.
Measured: Up to 5 years
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months.
Measured: Up to 5 years
Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the on-going care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months.
Measured: Up to 5 years
Preventive Care and Screening: Influenza Immunization
Percentage of patients, aged 6 months and older, seen for a visit between October 1 and March 31 who received an influenza immunization, or who reported previous receipt of an influenza immunization.
Measured: Up to 5 years
Pneumonia Vaccination Status for Older Adults
Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.
Measured: Up to 5 years
Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient
Percentage of patients aged 18 through 75 years with a diagnosis of diabetes mellitus who had a dilated eye exam.
Measured: Up to 5 years
Documentation of Current Medications in the Medical Record
Percentage of patients aged 18 years and older with a list of current medications (includes prescription, over-the-counter, herbals, vitamin/mineral/dietary nutritional supplements) documented by the provider, including drug name, dosage, frequency and route
Measured: Up to 5 years
Melanoma: Continuity of Care - Recall System
This measure is to be reported a minimum of once per reporting period for melanoma patients seen during the reporting period. It is anticipated that clinicians providing care for patients with melanoma or a history of melanoma will submit this measure.
Measured: Up to 5 years
Melanoma: Coordination of Care
This measure is to be reported at each visit occurring during the reporting period for melanoma patients seen during the reporting period. It is anticipated that clinicians providing care for patients with melanoma will submit this measure.
Measured: Up to 5 years
Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement
Percentage of patients aged 50 years and older with a diagnosis of AMD and/or their caregiver(s) who were counseled within 12 months on the benefits and/or risks of the Age-Related Eye Disease Study (AREDS) formulation for preventing progression of AMD
Measured: Up to 5 years
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% or Documentation of a Plan of Care
Percentages of patients aged 18 years and older with a diagnosis of POAG whose glaucoma treatment has not failed (the most recent IOP was reduced by at least 15% from the pre-intervention level) or if the most recent IOP was not reduced by at least 15% from the pre-intervention level, a plan of care was documented within 12 months.
Measured: Up to 5 years
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had best-corrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery.
Measured: Up to 5 years
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indicate the occurrence of any of the following major complications; retained nuclear fragments, endophthalmitis, dislocated or wrong power intraocular lens, retinal detachment, or wound dehiscence.
Measured: Up to 5 years
Melanoma: Overutilization of Imaging Studies in Melanoma
This measure is to be reported once per reporting period for patients with a current diagnosis of melanoma or a history of melanoma who are seen for an office visit during the reporting period. This measure is intended to reflect the quality of services provided for the primary management of patients with melanoma who have an office visit during the reporting period.
Measured: Up to 5 years
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months and who received cessation counseling intervention if identified as a tobacco user.
Measured: Up to 5 years
Controlling High Blood Pressure
Percentage of patients 18 through 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (< 140/90 mmHg) during the measurement period
Measured: Up to 5 years
Use of High-Risk Medications in the Elderly
Percentage of patients aged 66 years and older who were ordered high-risk medications.
Two rates are reported: 1. Percentage of patients who were ordered at least one high-risk medication. 2. Percentage of patients who were ordered at least two different high-risk medications.
Measured: Up to 5 years
Biopsy Follow-Up
Percentage of patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient by the performing physician
Measured: Up to 5 years
Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery
Percentage of patients aged 18 years and older in sample who had cataract surgery and had improvement in visual function achieved within 90 days following the cataract surgery, based on completing a pre-operative and postoperative visual function survey.
Measured: Up to 5 years
Patient Satisfaction within 90 Days Following Cataract Surgery
Percentage of patients aged 18 years and older in sample who had cataract surgery and were satisfied with their care within 90 days following the cataract surgery, based on completion of the Consumer Assessment of Healthcare Providers and Systems Surgical Care Survey.
Measured: Up to 5 years
Falls: Screening for Future Fall Risk
Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period.
Measured: Up to 5 years
Closing the Referral Loop: Receipt of Specialist Report
Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.
Measured: Up to 5 years
Adult Primary Rhegmatogenous Retinal Detachment Repair Success Rate
Percentage of surgeries for primary rhegmatogenous retinal detachment where the retina remains attached after only one surgery
Measured: Up to 5 years
Adult Primary Rhegmatogenous Retinal Detachment Surgery Success Rate
Percentage of retinal detachment cases achieving flat retinas six months post surgery
Measured: Up to 5 years
Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule requiring unplanned vitrectomy)
Rupture of the posterior capsule during anterior segment surgery requiring vitrectomy
Measured: Up to 5 years
Cataract Surgery: Difference Between Planned and Final Refraction
Percentage of patients who achieve planned refraction within +-1,0 D
Measured: Up to 5 years
Tobacco Use and Help with Quitting Among Adolescents
The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user.
Measured: Up to 5 years
Corneal Graft: 20/40 or Better Visual Acuity within 90 Days following Corneal Graft Surgery
Percentage of corneal graft surgery patients with a visual acuity of 20/40 or greater at 90 days after surgery
Measured: Up to 5 years
Open-Angle Glaucoma: Intraocular Pressure Reduction
Percentage of glaucoma patient visits where their IOP was below a threshold level based on the severity of their diagnosis
Measured: Up to 5 years
Open-Angle Glaucoma: Visual Field Progression
Percentage of eyes, in patients with a diagnosis of glaucoma, with a mean deviation loss of more than 3 decibels from their baseline value
Measured: Up to 5 years
Open-Angle Glaucoma: Intraocular Pressure Reduction Following Laser Trabeculoplasty
Percentage of patients underwent laser trabeculoplasty who had IOP reduced by 20% from their pretreatment level
Measured: Up to 5 years
Acquired Involutional Ptosis: Improvement of Marginal Reflex Distance within 90 Days Following Surgery for Acquired Involutional Ptosis
Percentage of surgical ptosis patients with an improvement of marginal reflex distance postoperatively
Measured: Up to 5 years
Acquired Involutional Entropion: Normalization of Eyelid Position within 90 Days Following Surgery for Acquired Involutional Entropion
Percentage of surgical entropion patients with a postoperative normalized lid position
Measured: Up to 5 years
Amblyopia: Improvement of Corrected Interocular Visual Acuity Difference to 2 or fewer Lines
Percentage of newly diagnosed amblyopic patients with a corrected interocular VA difference of 2 or fewer lines (< 0.23 logMAR) within 6 months of first diagnosis
Measured: Up to 5 years
Surgical Esotropia: Patients with Postoperative Alignment of 15 prism diopters or less
Percentage of surgical esotropia patients with a postoperative alignment of 15 prism diopters or less
Measured: Up to 5 years
Diabetic Retinopathy: Dilated Eye Exam
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months
Measured: Up to 5 years
Exudative Age-Related Macular Degeneration: Loss of Visual Acuity
Percentage of patients with a diagnosis of nonexudative age-related macular degeneration and taking AREDS supplements with of loss of less than 0.3 logMar of visual acuity within the past 12 months
Measured: Up to 5 years
Nonexudative Age-Related Macular Degeneration: Loss of Visual Acuity
Percentage of patients with nonexudative age-related macular degeneration progressing to exudative age-related macular degeneration over the past 12 months
Measured: Up to 5 years
Diabetic Macular Edema: Loss of Visual Acuity
Percentage of patients with a diagnosis of diabetic macular edema with of loss of less than 0.3 logMar of visual acuity within the past 12 months
Measured: Up to 5 years
Rhegmatogenous Retinal Detachment Surgery: Visual acuity improvement within 90 days of surgery
Percentage of patients who underwent rhegmatogenous retinal detachment surgery and achieved an improvement in their visual acuity from their preoperative level within 90 days of surgery in the treated eye.
Measured: Up to 5 years
Rhegmatogenous Retinal Detachment Surgery: Return to the operating room within 90 days of surgery
Percentage of patients who underwent rhegmatogenous retinal detachment surgery and had a return to the operating room within 90 days
Measured: Up to 5 years
Acute Anterior Uveitis: Post-treatment visual acuity
Percentage of acute anterior uveitis patients with a post-treatment best corrected visual acuity of 20/40 or greater OR patients whose visual acuity had returned to their baseline value prior to onset of uveitis
Measured: Up to 5 years
Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells
Percentage of patients with acute anterior uveitis post-treatment with Grade 0 anterior chamber cells
Measured: Up to 5 years
Chronic Anterior Uveitis: Post-treatment visual acuity
Percentage of chronic anterior uveitis patients with a post-treatment best corrected visual acuity of 20/40 or greater OR patients whose visual acuity had returned to their baseline value prior to onset of uveitis
Measured: Up to 5 years
Chronic Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells
Percentage of patients with chronic anterior uveitis post-treatment with Grade 0 anterior chamber cells
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2015 (estimated)
- Study startMar 2014
- Primary completionJan 2100 (estimated)
- Study completionJan 2100 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Eye DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20,000,000 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- American Academy of Ophthalmology
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Flora Lum, MD, Study director, American Academy of Ophthalmology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02485847
- Sponsor's protocol ID
- IRIS Registry
- Acronym
- IRISRegistry
- Status last verified
- Jul 2016
- First submitted
- 22 Jun 2015
- Last updated
- 12 Jul 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- IRIS Registry: Intelligent Research in Sight Registry
- ClinicalTrials.gov ID
- NCT02485847
- Acronym / sponsor ID
- IRISRegistry / IRIS Registry
- Conditions
- Eye Diseases
- Keywords
- Eye Diseases
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20,000,000 participants (estimated)
- Lead sponsor
- American Academy of OphthalmologyUniversity, hospital or other
- Study start
- Mar 2014
- Primary completion
- Jan 2100 (estimated)
- Study completion
- Jan 2100 (estimated)
- First posted
- 30 Jun 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The IRIS™ Registry (Intelligent Research in Sight) is the nation's first comprehensive eye disease clinical registry. The American Academy of Ophthalmology is developing it as part of the profession's shared goal of continual improvement in the delivery of eye care.The IRIS Registry will be a centralized system for ophthalmology practices to promote practice innovations and achieve clinical excellence.
Detailed description
The IRIS Registry is primarily a clinical self-improvement tool. It will allow ophthalmologists to compare their patient outcomes, professional performance and care processes against other ophthalmologists across the country. The IRIS Registry will be able to measure the continuum of care from initial patient contact, through intervention and follow up.
Improve Patient Care - Monitor patient interactions, track interventions, identify and address gaps in quality of care, and measure quality outcomes.
Manage Patient Populations - Proactively manage clinical conditions for entire patient populations by running reports on specific care criteria.
Benchmark Your Practice - Identify practice strengths and weaknesses using the IRIS Registry's ophthalmology-specific clinical data from other practices to compare to the performance and outcomes data of your practice.
Run quality reports on demand - Providing clinician- and practice-level results, plus national results and patient-level detail for all IRIS Registry measures.
Enhance Quality and Practice Efficiency - Use the IRIS Registry data to analyze practice processes and procedures and as a source for fact-based decision-making. Because the IRIS Registry will capture data over time at the individual and practice level, it will help practices efficiently manage patient care and optimize practice resources.
Join a Community of Quality - Become a member of a like-minded community of quality-driven professionals striving to continuously improve patient care. Interact with your peers to create opportunities for sharing quality improvement strategies and broaden your professional network.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
Who may qualify
- Ages
- 6 months and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- To ensure the IRIS Registry infrastructure is properly developed with features and functionalities that meets the needs of ophthalmologists, the IRIS Registry is currently only open to Academy members practicing in the United States and its territories.
Key inclusion criteria (1 listed)
- Patients who meet the denominator requirements for each measure.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OphthalmologyA registry of ophthalmic ambulatory encounters which captures essential data elements for continuous quality improvement efforts, enhanced patient care outcomes, and pay for performance programs. | Procedure or surgery | – |
Primary outcome
Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
Time frame: Up to 5 years
This measure is to be reported a minimum of once per reporting period for patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with primary open-angle glaucoma (in either one or both eyes) will submit this measure.
Age-Related Macular Degeneration (AMD): Dilated Macular Examination
Time frame: Up to 5 years
This measure is to be reported a minimum of once per reporting period for patients, aged 50 years and older, seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with age-related macular degeneration (in either one or both eyes) will submit this measure.
Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
Time frame: Up to 5 years
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months.
Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care
Time frame: Up to 5 years
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the on-going care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months.
Preventive Care and Screening: Influenza Immunization
Time frame: Up to 5 years
Percentage of patients, aged 6 months and older, seen for a visit between October 1 and March 31 who received an influenza immunization, or who reported previous receipt of an influenza immunization.
Pneumonia Vaccination Status for Older Adults
Time frame: Up to 5 years
Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.
Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient
Time frame: Up to 5 years
Percentage of patients aged 18 through 75 years with a diagnosis of diabetes mellitus who had a dilated eye exam.
Documentation of Current Medications in the Medical Record
Time frame: Up to 5 years
Percentage of patients aged 18 years and older with a list of current medications (includes prescription, over-the-counter, herbals, vitamin/mineral/dietary nutritional supplements) documented by the provider, including drug name, dosage, frequency and route
Melanoma: Continuity of Care - Recall System
Time frame: Up to 5 years
This measure is to be reported a minimum of once per reporting period for melanoma patients seen during the reporting period. It is anticipated that clinicians providing care for patients with melanoma or a history of melanoma will submit this measure.
Melanoma: Coordination of Care
Time frame: Up to 5 years
This measure is to be reported at each visit occurring during the reporting period for melanoma patients seen during the reporting period. It is anticipated that clinicians providing care for patients with melanoma will submit this measure.
Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement
Time frame: Up to 5 years
Percentage of patients aged 50 years and older with a diagnosis of AMD and/or their caregiver(s) who were counseled within 12 months on the benefits and/or risks of the Age-Related Eye Disease Study (AREDS) formulation for preventing progression of AMD
Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% or Documentation of a Plan of Care
Time frame: Up to 5 years
Percentages of patients aged 18 years and older with a diagnosis of POAG whose glaucoma treatment has not failed (the most recent IOP was reduced by at least 15% from the pre-intervention level) or if the most recent IOP was not reduced by at least 15% from the pre-intervention level, a plan of care was documented within 12 months.
Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
Time frame: Up to 5 years
Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had best-corrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery.
Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
Time frame: Up to 5 years
Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indicate the occurrence of any of the following major complications; retained nuclear fragments, endophthalmitis, dislocated or wrong power intraocular lens, retinal detachment, or wound dehiscence.
Melanoma: Overutilization of Imaging Studies in Melanoma
Time frame: Up to 5 years
This measure is to be reported once per reporting period for patients with a current diagnosis of melanoma or a history of melanoma who are seen for an office visit during the reporting period. This measure is intended to reflect the quality of services provided for the primary management of patients with melanoma who have an office visit during the reporting period.
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Time frame: Up to 5 years
Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months and who received cessation counseling intervention if identified as a tobacco user.
Controlling High Blood Pressure
Time frame: Up to 5 years
Percentage of patients 18 through 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (< 140/90 mmHg) during the measurement period
Use of High-Risk Medications in the Elderly
Time frame: Up to 5 years
Percentage of patients aged 66 years and older who were ordered high-risk medications. Two rates are reported: 1. Percentage of patients who were ordered at least one high-risk medication. 2. Percentage of patients who were ordered at least two different high-risk medications.
Biopsy Follow-Up
Time frame: Up to 5 years
Percentage of patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient by the performing physician
Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery
Time frame: Up to 5 years
Percentage of patients aged 18 years and older in sample who had cataract surgery and had improvement in visual function achieved within 90 days following the cataract surgery, based on completing a pre-operative and postoperative visual function survey.
Patient Satisfaction within 90 Days Following Cataract Surgery
Time frame: Up to 5 years
Percentage of patients aged 18 years and older in sample who had cataract surgery and were satisfied with their care within 90 days following the cataract surgery, based on completion of the Consumer Assessment of Healthcare Providers and Systems Surgical Care Survey.
Falls: Screening for Future Fall Risk
Time frame: Up to 5 years
Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period.
Closing the Referral Loop: Receipt of Specialist Report
Time frame: Up to 5 years
Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.
Adult Primary Rhegmatogenous Retinal Detachment Repair Success Rate
Time frame: Up to 5 years
Percentage of surgeries for primary rhegmatogenous retinal detachment where the retina remains attached after only one surgery
Adult Primary Rhegmatogenous Retinal Detachment Surgery Success Rate
Time frame: Up to 5 years
Percentage of retinal detachment cases achieving flat retinas six months post surgery
Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule requiring unplanned vitrectomy)
Time frame: Up to 5 years
Rupture of the posterior capsule during anterior segment surgery requiring vitrectomy
Cataract Surgery: Difference Between Planned and Final Refraction
Time frame: Up to 5 years
Percentage of patients who achieve planned refraction within +-1,0 D
Tobacco Use and Help with Quitting Among Adolescents
Time frame: Up to 5 years
The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user.
Corneal Graft: 20/40 or Better Visual Acuity within 90 Days following Corneal Graft Surgery
Time frame: Up to 5 years
Percentage of corneal graft surgery patients with a visual acuity of 20/40 or greater at 90 days after surgery
Open-Angle Glaucoma: Intraocular Pressure Reduction
Time frame: Up to 5 years
Percentage of glaucoma patient visits where their IOP was below a threshold level based on the severity of their diagnosis
Open-Angle Glaucoma: Visual Field Progression
Time frame: Up to 5 years
Percentage of eyes, in patients with a diagnosis of glaucoma, with a mean deviation loss of more than 3 decibels from their baseline value
Open-Angle Glaucoma: Intraocular Pressure Reduction Following Laser Trabeculoplasty
Time frame: Up to 5 years
Percentage of patients underwent laser trabeculoplasty who had IOP reduced by 20% from their pretreatment level
Acquired Involutional Ptosis: Improvement of Marginal Reflex Distance within 90 Days Following Surgery for Acquired Involutional Ptosis
Time frame: Up to 5 years
Percentage of surgical ptosis patients with an improvement of marginal reflex distance postoperatively
Acquired Involutional Entropion: Normalization of Eyelid Position within 90 Days Following Surgery for Acquired Involutional Entropion
Time frame: Up to 5 years
Percentage of surgical entropion patients with a postoperative normalized lid position
Amblyopia: Improvement of Corrected Interocular Visual Acuity Difference to 2 or fewer Lines
Time frame: Up to 5 years
Percentage of newly diagnosed amblyopic patients with a corrected interocular VA difference of 2 or fewer lines (< 0.23 logMAR) within 6 months of first diagnosis
Surgical Esotropia: Patients with Postoperative Alignment of 15 prism diopters or less
Time frame: Up to 5 years
Percentage of surgical esotropia patients with a postoperative alignment of 15 prism diopters or less
Diabetic Retinopathy: Dilated Eye Exam
Time frame: Up to 5 years
Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed which included documentation of the level of severity of retinopathy and the presence or absence of macular edema during one or more office visits within 12 months
Exudative Age-Related Macular Degeneration: Loss of Visual Acuity
Time frame: Up to 5 years
Percentage of patients with a diagnosis of nonexudative age-related macular degeneration and taking AREDS supplements with of loss of less than 0.3 logMar of visual acuity within the past 12 months
Nonexudative Age-Related Macular Degeneration: Loss of Visual Acuity
Time frame: Up to 5 years
Percentage of patients with nonexudative age-related macular degeneration progressing to exudative age-related macular degeneration over the past 12 months
Diabetic Macular Edema: Loss of Visual Acuity
Time frame: Up to 5 years
Percentage of patients with a diagnosis of diabetic macular edema with of loss of less than 0.3 logMar of visual acuity within the past 12 months
Rhegmatogenous Retinal Detachment Surgery: Visual acuity improvement within 90 days of surgery
Time frame: Up to 5 years
Percentage of patients who underwent rhegmatogenous retinal detachment surgery and achieved an improvement in their visual acuity from their preoperative level within 90 days of surgery in the treated eye.
Rhegmatogenous Retinal Detachment Surgery: Return to the operating room within 90 days of surgery
Time frame: Up to 5 years
Percentage of patients who underwent rhegmatogenous retinal detachment surgery and had a return to the operating room within 90 days
Acute Anterior Uveitis: Post-treatment visual acuity
Time frame: Up to 5 years
Percentage of acute anterior uveitis patients with a post-treatment best corrected visual acuity of 20/40 or greater OR patients whose visual acuity had returned to their baseline value prior to onset of uveitis
Acute Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells
Time frame: Up to 5 years
Percentage of patients with acute anterior uveitis post-treatment with Grade 0 anterior chamber cells
Chronic Anterior Uveitis: Post-treatment visual acuity
Time frame: Up to 5 years
Percentage of chronic anterior uveitis patients with a post-treatment best corrected visual acuity of 20/40 or greater OR patients whose visual acuity had returned to their baseline value prior to onset of uveitis
Chronic Anterior Uveitis: Post-treatment Grade 0 anterior chamber cells
Time frame: Up to 5 years
Percentage of patients with chronic anterior uveitis post-treatment with Grade 0 anterior chamber cells
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jul 2016.
- IRIS Registry web siteLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Eye Diseases
Not yet recruitingPhase 2
A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis
Blepharitis
Not yet recruiting
PAUL® Glaucoma Implant Safety and Effectiveness Study
Refractory Glaucoma
Not yet recruitingObservational study
Corneal Biomechanics and Stromal Tissue Characteristics in Patients Undergoing SMILE
Myopia
Active, not recruitingPhase 4
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
Geographic Atrophy, Age-Related Macular Degeneration
RecruitingPhase 2
A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)
Participants With Underactive Bladder (UAB)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Flora Lum, MD study director
American Academy of Ophthalmology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Eye Diseases, run by American Academy of Ophthalmology at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andy Khuong (415-561-8500, irisregistry@aao.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation (time frame: Up to 5 years). The study lists 46 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2016.